secwatch.observer — SEC 8-K summary
======================================

Issuer:     RELMADA THERAPEUTICS, INC. (RLMD)
CIK:        0001553643
Form:       8-K
Filed at:   2025-07-10T23:59:59+00:00
Accession:  0001213900-25-062803
Event type: other_material
Sentiment:  negative
Materiality: 0.60
Item codes: 1.02
LLM model:  deepseek-v4-flash:cloud@v2

Relmada terminates esmethadone license agreement with Inturrisi and Manfredi
----------------------------------------------------------------------------

- On July 7, 2025, Relmada delivered termination notice for the esmethadone License Agreement with Drs. Inturrisi and Manfredi.
- The agreement granted exclusive worldwide license for esmethadone in psychiatric use; obligations cease 90 days after notice.
- Relmada had been paying $45,000 quarterly under the agreement; upfront fee of $180,000 paid in 2018.
- The termination ends Relmada's participation in the previously announced esmethadone development program.
- No commercial sales, royalties, or sublicense payments had occurred under the agreement.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1553643/000121390025062803/0001213900-25-062803-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1553643/000121390025062803/ea0248503-8k_relmada.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-062803

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer